Gualberto Gussoni Selected Research

apixaban

5/2022	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
1/2022	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
5/2021	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
1/2020	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
9/2018	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gualberto Gussoni Research Topics

Disease

11	Neoplasms (Cancer) 05/2022 - 06/2005
8	Venous Thromboembolism 05/2022 - 10/2010
7	Hemorrhage 05/2022 - 08/2006
4	Pulmonary Embolism 01/2020 - 06/2005
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2020 - 06/2005
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 05/2022 - 05/2021
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2020
2	Chronic Obstructive Pulmonary Disease (COPD) 04/2021 - 10/2016
2	Ischemic Stroke 12/2019 - 06/2013
2	Atrial Fibrillation 04/2017 - 06/2013
1	Urogenital Neoplasms 05/2022
1	Heart Failure 11/2021
1	Hyperkalemia 11/2021
1	Thrombosis (Thrombus) 05/2021
1	Disease Progression 05/2021
1	Body Weight (Weight, Body) 01/2020
1	Infections 12/2019
1	Frailty 01/2018
1	Cognitive Dysfunction 01/2018
1	Pain (Aches) 01/2018
1	Stroke (Strokes) 04/2017
1	Embolism (Embolus) 04/2017
1	Type 2 Diabetes Mellitus (MODY) 10/2014
1	Peripheral Arterial Disease 11/2013
1	Thromboembolism 10/2009
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2009
1	Hypotension (Low Blood Pressure) 08/2006
1	Ischemia 08/2006
1	Thrombophlebitis 06/2005

Drug/Important Bio-Agent (IBA)

6	AnticoagulantsIBA 05/2022 - 06/2013
5	Dalteparin (Dalteparin Sodium)FDA Link 05/2022 - 09/2018
5	apixabanIBA 05/2022 - 09/2018
5	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 05/2021 - 10/2009
3	RivaroxabanIBA 01/2022 - 01/2020
2	Iloprost (Ventavis)FDA Link 11/2013 - 08/2006
1	sodium zirconium cyclosilicateIBA 11/2021
1	patiromerIBA 11/2021
1	PotassiumIBA 11/2021
1	SmokeIBA 04/2021
1	edoxabanIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2019
1	prulifloxacinIBA 10/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2016
1	Levofloxacin (Levaquin)FDA Link 10/2016
1	Pain-FreeIBA 11/2013
1	Nadroparin (Nadroparin Calcium)IBA 10/2009

Therapy/Procedure

2	Therapeutics 11/2021 - 01/2018
2	Central Venous Catheters 12/2019 - 06/2005
2	Length of Stay 12/2019 - 01/2007
1	Activities of Daily Living (ADL) 01/2018
1	Secondary Prevention 04/2017
1	Glycemic Control 10/2014
1	Subacute Care 10/2010
1	Drug Therapy (Chemotherapy) 10/2009
1	Subcutaneous Injections 10/2009
1	Bed Rest (Bedrest) 01/2006
1	Anesthesia 01/2006
1	Catheters 06/2005